“It’s a very severe pain, often times throbbing occurring on one side of the head, often times behind the eye,” Dr. Sugimoto said. “You’ll do anything to get rid of that pain.”
At the Cedar-Crosse Research Center in Chicago’s South Loop, a study called ‘Promise One’ is hoping to give migraine sufferers the relief they’ve been looking for.
The drug is called ‘ALD403.’ It’s given to a patient through an I-V once for an hour, every three months.
It is now in phase three of the trial before it goes to the Food and Drug Administration for approval. That approval could come in the next two to three years.
But for potential trial patients like Spiller, the drug could be a life line.
“It for me would mean to get my life back. That’s what it means to me. For me to live and not just exist which is what I’ve basically been doing,” Spiller said.
